Last reviewed · How we verify
NCT04781413
Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer
Phase 1, PHASE2 trial testing Nab-PTX, Sintilimab, S-1 in Stage IIIC Gastric Cancer in 38 participants. Status unknown.
1 March 2024
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 38 |
| Start date | 1 March 2021 |
| Primary completion | 1 March 2024 |
| Estimated completion | 1 March 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Nab-PTX, Sintilimab, S-1 — full drug profile →
Conditions studied
- Stage IIIC Gastric Cancer — all drugs for Stage IIIC Gastric Cancer →
Sponsor
Ruijin Hospital
Who can join
Adults 18 to 80, any sex, with Stage IIIC Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, we combine Nab-PTX, S-1 and sintilimab as adjuvant regimen to patients with stage IIIC GC. We are aiming to investigate the recommended dose of this regimen in a phase I study and estimate the toxicity and efficacy of this regimen in a phase II study.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cancer nanomedicine: a review of nano-therapeutics and challenges ahead.
Nirmala MJ, Kizhuveetil U, Johnson A, G B, et al · · 2023 · cited 86× · PMID 36926304 · DOI 10.1039/d2ra07863e -
Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
Mei Y, Shi M, Zhu Z, Yuan H, et al · · 2022 · cited 6× · PMID 34877867 · DOI 10.2217/fon-2021-1020 -
Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?
Timon-David E, Perez C, Rodallec A. · · 2022 · cited 2× · PMID 36365144 · DOI 10.3390/pharmaceutics14112326 -
Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer.
Javanmehr N, Ashtyani AM, Ghafelehbashi R, Mousavi F, et al · · 2026 · PMID 42095302 · DOI 10.1002/iid3.70437
Verify or expand the search:
- PubMed search for NCT04781413
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04781413 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 4 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04781413.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing